Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease

Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease

Alanine–serine–cysteine transporter 2 (ASCT2) is reported to participate in the progression of tumors and metabolic diseases. It is also considered to play a crucial role in the glutamate-glutamine shuttle of neuroglial network. However, it remains unclear the involvement of ASCT2 in neurological di...

Full description

Bibliographic Details
Main Authors: Yang Liu, Ting Liu, Yuanzhang Zhou, Wenjie Li, Min Wang, Nanshan Song, Wenbin Zhang, Jingwei Jiang, Shengtao Yuan, Jianhua Ding, Gang Hu, Ming Lu
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:Acta Pharmaceutica Sinica B
Subjects:
ASCT2
NLRP3
Astrocytes
Inflammation
Neurodegeneration
Drug screening
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522003343

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522003343

Similar Items